{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:43:13Z","timestamp":1779230593861,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.leukres.2005.10.024","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T12:20:52Z","timestamp":1133871652000},"page":"801-811","source":"Crossref","is-referenced-by-count":45,"title":["The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)"],"prefix":"10.1016","volume":"30","author":[{"given":"Francis J.","family":"Giles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bycott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdi","family":"Pithavala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Steinfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen W.L.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2005.10.024_bib1","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib2","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cncr.10900","article-title":"Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes","volume":"95","author":"Aguayo","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2005.10.024_bib3","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia","volume":"95","author":"Padro","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.V89.6.1870","article-title":"Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia","volume":"89","author":"Fiedler","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V95.1.309","article-title":"Evidence of increased angiogenesis in patients with acute myeloid leukemia","volume":"95","author":"Hussong","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib6","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.leu.2402534","article-title":"Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia","volume":"16","author":"Padro","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.10.024_bib7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib8","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1182\/blood.V94.11.3717","article-title":"Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia","volume":"94","author":"Aguayo","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","article-title":"Angiogenesis in myelodysplastic syndromes","volume":"81","author":"Pruneri","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2005.10.024_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2005.10.024_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1172\/JCI8978","article-title":"Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration","volume":"106","author":"Dias","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2005.10.024_bib12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/sj.leu.2400722","article-title":"Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia","volume":"11","author":"Fielder","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.10.024_bib13","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood.V99.6.2179","article-title":"Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy","volume":"99","author":"Dias","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib14","unstructured":"Pfizer, Inc. Investigator's Brochure, version January 20, 2004."},{"key":"10.1016\/j.leukres.2005.10.024_bib15","first-page":"669","article-title":"The expression of the proto-oncogene c-kit in the blast cells of acute myeloid leukemia","volume":"3","author":"Wang","year":"1989","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.10.024_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ajcp\/106.2.192","article-title":"CD117\/CD34 expression in leukemic blasts","volume":"106","author":"Wells","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.leukres.2005.10.024_bib17","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood.V78.11.2962.2962","article-title":"Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells","volume":"78","author":"Ikeda","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood.V80.1.60.60","article-title":"Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor","volume":"80","author":"Broudy","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V88.1.319.319","article-title":"Role of cytokines in leukemic type growth of myelodysplastic CD34+ cells","volume":"88","author":"Sawada","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1034\/j.1600-0609.2001.0430a.x","article-title":"Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts","volume":"67","author":"Foss","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2005.10.024_bib21","first-page":"1082","article-title":"Pharmacological activities of AG013736, a small molecule inhibitor of VEGF\/PDGR[F] receptor tyrosine kinases","volume":"43","author":"Hu-Lowe","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.leukres.2005.10.024_bib22","first-page":"1082","article-title":"Characterization of potency and activity of the VEGF\/PDGF receptor tyrosine kinase inhibitor AG013736","volume":"43","author":"Hu-Lowe","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.leukres.2005.10.024_bib23","first-page":"752","article-title":"Further characterization of the potent VEGF\/PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitumor activity","volume":"44","author":"Wickman","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.leukres.2005.10.024_bib24","article-title":"PK\/PD modeling based on mouse xenograft tumor growth inhibition and the correlation to clinical exposure for VEGF\/PDGF receptor tyrosine kinase inhibitor AG-013736","volume":"46","author":"Yamazaki","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.leukres.2005.10.024_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2005.10.024_bib26","doi-asserted-by":"crossref","unstructured":"Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. Phase I trial of the oral anti-angiogenesis agent AG-013736 in patients with advanced solid tumors\u2014pharmacokinetic and clinical results. J Clin Oncol 2005 July 18 [Epub ahead of print].","DOI":"10.1200\/JCO.2005.04.192"},{"key":"10.1016\/j.leukres.2005.10.024_bib27","series-title":"Common toxicity criteria manual, version 3. 0","author":"CTEP","year":"2003"},{"key":"10.1016\/j.leukres.2005.10.024_bib28","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.024_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199101033240101","article-title":"Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma","volume":"324","author":"Weidner","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.10.024_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.leukres.2005.10.024_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0609.1998.tb01042.x","article-title":"Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia","volume":"60","author":"Tajima","year":"1998","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2005.10.024_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.1995.tb05239.x","article-title":"Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders","volume":"91","author":"Kawakita","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.10.024_bib34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1634\/theoncologist.6-suppl_5-32","article-title":"The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies","volume":"6","author":"Giles","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2005.10.024_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1040-8428(00)00122-0","article-title":"Acute myeloid leukemia in the elderly: biology and therapeutic strategies","volume":"39","author":"Pinto","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.leukres.2005.10.024_bib37","first-page":"9a","article-title":"Successful long-term therapy with bevacizumab (Avastin\u2122) in solid tumors","volume":"21","author":"Langmuir","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.024_bib38","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.024_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-004-2699-3","article-title":"Angiogenic growth factors and hypertension","volume":"7","author":"Sane","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.leukres.2005.10.024_bib40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"Role of the microvascular endothelium in progressive renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.leukres.2005.10.024_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2005.10.024_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1749-6632.2002.tb04871.x","article-title":"Insights into the molecular pathogenesis and targeted treatment of lymphedema","volume":"979","author":"Saaristo","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.leukres.2005.10.024_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/019459989010200103","article-title":"Description and clinical importance of the lymphatics of the vocal fold","volume":"102","author":"Werner","year":"1990","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.leukres.2005.10.024_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1044\/1092-4388(2002\/021)","article-title":"Biological mechanisms underlying voice changes due to dehydration","volume":"45","author":"Verdolini","year":"2002","journal-title":"J Speech Lang Hear Res"},{"key":"10.1016\/j.leukres.2005.10.024_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.2002.03551.x","article-title":"Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome","volume":"118","author":"Verstovsek","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.10.024_bib46","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.exphem.2004.03.005","article-title":"Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells","volume":"32","author":"List","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2005.10.024_bib47","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/bjc.1992.255","article-title":"Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia","volume":"66","author":"Gruber","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2005.10.024_bib49","doi-asserted-by":"crossref","first-page":"25915","DOI":"10.1074\/jbc.270.43.25915","article-title":"Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells","volume":"270","author":"Grugel","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2005.10.024_bib50","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1073\/pnas.95.7.3609","article-title":"Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor\/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells","volume":"95","author":"Okada","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2005.10.024_bib51","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.leu.2403145","article-title":"Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras\/PI3-K\/PKB-dependent pathway","volume":"18","author":"Birkenkamp","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.10.024_bib53","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2141.1998.01076.x","article-title":"Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth","volume":"103","author":"Ratajczak","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.10.024_bib54","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.V83.8.2145.2145","article-title":"Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor","volume":"83","author":"Broudy","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib55","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood.V87.3.847.bloodjournal873847","article-title":"Soluble cytokine receptors","volume":"87","author":"Heaney","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib56","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"Carmeliet","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2005.10.024_bib57","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2005.10.024_bib58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/bbrc.1996.1355","article-title":"Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR","volume":"226","author":"Kendall","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.leukres.2005.10.024_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood.V85.1.66.bloodjournal85166","article-title":"Soluble kit receptor in human serum","volume":"85","author":"Wypych","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.024_bib60","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1016\/S0021-9258(19)49629-4","article-title":"Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor","volume":"267","author":"Lev","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2005.10.024_bib61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/excr.1998.4039","article-title":"Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2","volume":"241","author":"Roeckl","year":"1998","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.leukres.2005.10.024_bib62","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/cncr.20187","article-title":"Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes","volume":"100","author":"Hu","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2005.10.024_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0037-1616197","article-title":"Angiogenesis research: guidelines for translation to clinical application","volume":"86","author":"Folkman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.leukres.2005.10.024_bib64","first-page":"234a","article-title":"Analysis of biomarkers of SU11248 action in an exploratory study of patients with advanced malignancies","volume":"22","author":"O\u2019Farrell","year":"2003","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605004248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605004248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T01:35:36Z","timestamp":1626831336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212605004248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0145212605004248"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2005.10.024","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}